Piscataway, NJ, May 15, 2025 –Camber Pharmaceuticals is excited to announce the addition of Temozolomide Capsules, USP to the portfolio.
Temozolomide Capsules, USP is an alkylating drug indicated for the treatment of adults with:
- Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment
- Anaplastic astrocytoma
- Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma
- Treatment of adults with refractory anaplastic astrocytoma
Temozolomide Capsules, USP are available in the following strengths and sizes:
- 5 mg- 5 and 14 count
- 20 mg- 5 and 14 count
- 100 mg- 5 and 14 count
- 140 mg- 5 and 14 count
- 180 mg- 5 and 14 count
- 250 mg- 5 count
To find out more information on Temozolomide Capsules, USP, please visit: www.camberpharma.com/temozolomide
